POINT Biopharma Global (NASDAQ:PNT – Get Rating) is one of 942 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare POINT Biopharma Global to related businesses based on the strength of its valuation, institutional ownership, dividends, earnings, analyst recommendations, risk and profitability.
This is a summary of current ratings for POINT Biopharma Global and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|POINT Biopharma Global||1||0||4||0||2.60|
|POINT Biopharma Global Competitors||2590||12276||38408||606||2.69|
Earnings and Valuation
This table compares POINT Biopharma Global and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|POINT Biopharma Global||N/A||-$45.90 million||-11.59|
|POINT Biopharma Global Competitors||$1.86 billion||$250.59 million||-2.61|
POINT Biopharma Global’s peers have higher revenue and earnings than POINT Biopharma Global. POINT Biopharma Global is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
POINT Biopharma Global has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, POINT Biopharma Global’s peers have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.
Institutional & Insider Ownership
41.8% of POINT Biopharma Global shares are held by institutional investors. Comparatively, 45.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares POINT Biopharma Global and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|POINT Biopharma Global||N/A||-21.54%||-20.72%|
|POINT Biopharma Global Competitors||-3,136.96%||-1,455.34%||-9.04%|
POINT Biopharma Global peers beat POINT Biopharma Global on 9 of the 13 factors compared.
About POINT Biopharma Global (Get Rating)
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.